Zynerba Up On Second Patent For Cannabidiol Candidate In 2019
Zacks Investment Research | Jun 11, 2019 09:39PM ET
Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) announced issuance of a new U.S. patent covering cannabidiol, a key compound of its lead pipeline candidate, Zygel, for treating autism spectrum disorder. The U.S. Patent and Trademark Office issued US Patent No. 10,314,792, which includes claims directed to methods of treating autism spectrum disorder through administration of a therapeutically effective amount of synthetic cannabidiol. The patent will expire in 2038.
Last month, the company initiated a phase II study to evaluate Zygel in pediatric patients with autism spectrum disorder.
We remind investors that Zynerba was awarded another methods of treating patent in February, covering synthetic or purified cannabidiol for the treatment of Fragile X syndrome, a genetic disorder causing certain developmental problems in patients. With the issuance of the new patent, the company owns 11 patents covering its pipeline products.
Shares of the company rallied 16.6% on Jun 11 as the new patent issuance strengthens its intellectual property portfolio covering Zygel. Zynerba’s shares have surged 354.5% so far this year against the filed for bankruptcy earlier this week.
Zynerba Pharmaceuticals, Inc. Price
Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.